Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
3.840
-0.050 (-1.29%)
Mar 17, 2026, 11:18 AM EDT - Market open

Tvardi Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
2.577.1420.9741.8723.03135.08
Revenue Growth (YoY)
-50.01%-65.96%-49.92%81.81%-82.95%579.28%
Cost of Revenue
-0.626.177.27--
Gross Profit
2.576.5214.7934.6--
Selling, General & Admin
16.8726.5327.7830.2629.4121.85
Research & Development
9.932.81108.5191.8882.7107.85
Other Operating Expenses
-5.57----
Total Operating Expenses
26.7664.9136.29122.14112.11129.7
Operating Income
-24.2-58.38-121.5-87.54-89.085.39
Interest Income
0.79-----
Interest Expense
-2.87-8.47-0.6---
Other Non-Operating Income (Expense)
15.83-4.413.592.060.642.33
Total Non-Operating Income (Expense)
13.76-12.882.982.060.642.33
Pretax Income
-10.44-71.27-118.51-85.47-88.447.72
Provision for Income Taxes
--0.4----0.69
Net Income
-13.95-70.87-118.51-85.47-88.448.41
Net Income to Common
-13.95-70.87-118.51-85.47-88.448.41
Shares Outstanding (Basic)
221919111
Shares Outstanding (Diluted)
221919111
Shares Change (YoY)
980.92%0.31%1183.84%5.79%5.85%12.29%
EPS (Basic)
1.65-1.53-0.91-57.36-62.646.48
EPS (Diluted)
0.14-1.53-0.91-57.36-62.646.48
Free Cash Flow
-21.86-61.96-94.45-78.77-60.13-5.84
Free Cash Flow Per Share
-0.99-3.23-4.94-52.85-42.68-4.38
Gross Margin
100.00%91.31%70.56%82.65%100.00%100.00%
Operating Margin
-669.25%-818.03%-579.43%-209.08%-386.85%3.99%
Profit Margin
-562.51%-992.95%-565.21%-204.16%-384.06%6.23%
FCF Margin
-850.80%-868.19%-450.46%-188.15%-261.10%-4.32%
EBITDA
-17.15-58.19-121.24-87.29-88.845.59
EBITDA Margin
-667.40%-815.34%-578.20%-208.49%-385.77%4.14%
EBIT
-24.2-58.38-121.5-87.54-89.085.39
EBIT Margin
-669.25%-818.03%-579.43%-209.08%-386.85%3.99%
Effective Tax Rate
-0.56%0.00%0.00%0.00%-8.95%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q